Asad Islam, MD
Psychiatry · Lewisville, TXNPI 1841248846
Payments from drug & device makers
Across 1,424 payments — averaging $260.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$126K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$113K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$29K
- AbbVie$28K
- Eli Lilly$23K
- E.r. Squibb & Sons, L.L.C.$23K
- plus $28K from 35 others
Across 1 payment — averaging $2388.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$9004%
- Speaking & faculty fees$5002%
- Travel & lodging$2441%
- Food & beverage$20,12690%
- Education$7013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wakix$1,048
- INGREZZA$202
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- ABILIFY MAINTENA$123
- SPRAVATO$119
- QELBREE$118
- SUNOSI$107
- Jornay PM 20mg capsules (Bottle of 100)$101
How this compares
$370,299 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $297,769 |
| Austedo XrDeutetrabenazine | 14 | $118,604 |
| RexultiBrexpiprazole | 40 | $69,682 |
| VraylarCariprazine Hcl | 44 | $64,728 |
| CaplytaLumateperone Tosylate | 15 | $28,029 |
| SpravatoEsketamine Hcl | 24 | $27,204 |
| TrintellixVortioxetine Hydrobromide | 26 | $25,962 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $19,440 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $15,783 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $9,679 |
| Duloxetine Hcl | 363 | $9,180 |
| Quetiapine Fumarate | 427 | $8,289 |
| Aripiprazole | 76 | $5,691 |
| KlonopinClonazepam | 13 | $5,180 |
| BelsomraSuvorexant | 12 | $5,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,421 | $297,76931 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,806 | $118,60414 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,440 | $69,68240 claims |
| AbbVieVraylar | $28,360 | $64,72844 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $476 | $35,64152 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $29,069 | $28,02915 claims |
| Johnson & JohnsonSpravato | $1,783 | $27,20424 claims |
| Alkermes, Inc.Lybalvi | $1,449 | $19,44011 claims |
| Axsome Therapeutics, Inc.Auvelity | $300 | $15,78312 claims |
| MerckBelsomra | $36 | $5,14112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Lewisville
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.